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Summary
Aim Patients with classic congenital adrenal hyperplasia (CAH)
have poor health outcomes. In the absence of a comprehensive
observational study, this manuscript provides a model to esti-
mate the lifetime disease burden of adults with classic CAH.
Methods The model, built in Excel, comprises subdomains
addressing the health consequences of CAH and synthesises evi-
dence from clinical and epidemiological studies on health out-
comes.
Results The model estimates that adults with classic CAH will
implement ‘sick day rules’ (doubling or tripling glucocorticoid
and/or use of parenteral therapy) 171 times over their lifetime
and attend hospital for adrenal crisis on 11 occasions. In a pop-
ulation of 1000, over 200 will die of a condition complicated by
adrenal crisis resulting, on average, in a loss of 7 years of life.
Patients with CAH may also suffer from excess CVD events.
Treatment with glucocorticoids almost doubles the risk of bone
fractures in patients with CAH compared to the general popula-
tion, leading on average to an additional 08 fractures per
patient with CAH over their lifetime.
Conclusions The disease burden model highlights gaps in evi-
dence, particularly regarding intensity of care and adrenal crisis,
and the relationship between control of CAH and risks of CVD,
osteoporosis, diabetes and infertility. The model can be used for
research on the impact of new clinical pathways and therapeutic
interventions in terms of clinical events and cost.
(Received 5 January 2016; returned for revision 3 February 2016;
finally revised 26 February 2016; accepted 15 March 2016)
Introduction
Congenital adrenal hyperplasia (CAH) is the commonest con-
genital endocrine disorder, arising from defective steroidogene-
sis.1 The most frequent mutation is in the gene encoding 21-
hydroxylase (21-OH) resulting in failure of cortisol synthesis
and consequently increased pituitary adrenocorticotropic hor-
mone (ACTH) release, which in turn promotes overproduction
of 17-hydroxyprogesterone (17-OHP), progesterone and adrenal
androgens – termed classic CAH. Patients with CAH due to 21-
OH deficiency have two major problems: cortisol deficiency and
androgen excess. In addition, many patients also have mineralo-
corticoid deficiency as 21-OH mediates a key step in aldosterone
synthesis. The clinical classification of 21-OH deficiency is based
on the severity of mutations. The most severe classic form
occurs in about 1 in 15 000 births.2 The classic form usually
presents early in life or at neonatal screening and comprises salt
wasting and simple virilising subgroups based on whether the
severity of aldosterone deficiency causes a salt-wasting hypoten-
sive crisis in the newborn. Classic CAH is characterized by sex-
ual ambiguity at birth in females, and by precocious puberty,
short stature and fertility problems in both males and females.
Treatment of CAH is by glucocorticoid and mineralocorticoid
replacement. However, this presents a challenge as no current
glucocorticoid regimen replicates the normal circadian rhythm
of cortisol. There is no consensus on what glucocorticoid regi-
men to use in adults with CAH, and patients receive a variety of
treatments including hydrocortisone, prednisolone, prednisone
and dexamethasone give in a circadian or reverse circadian fash-
ion.3,4 As a result, glucocorticoid under- and overtreatment is a
risk and is linked to complications including adrenal crisis, obe-
sity, hyperlipidaemia, hypertension, cardiovascular disease
(CVD) and reduced bone mineral density (BMD).5 Health-
related quality of life (HRQoL) has been variously reported
reduced in some studies and normal in others.3,6,7
The need for regular physician visits to manage and adjust
treatment, the risk of adrenal crisis (AC) and the long-term
impacts of both CAH symptoms and glucocorticoid therapy lead
to a considerable burden on the health service. This is the first
study to model and estimate the disease burden and excess mor-
tality associated with classic CAH in adults.
Methods and model
Model overview
The model computes life years (LYs) and quality-adjusted life
years (QALYs) for adults with classic CAH compared to the gen-
eral population. The QALY is a measure of health that attempts
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to capture mortality and morbidity. The impact of morbidity on
the patient is measured in terms of health-related quality of life
(HRQoL), using a single scale anchored on one (which repre-
sents perfect health) and zero (which represents death). QALYs
are then calculated by multiplying the HRQoL value with the
length of life spent in that health state, for example 10 years at
05, produces 5 QALYs. This approach can be extended to esti-
mate the QALYs across complex chronic disease profiles. Whilst
the QALY is too crude to be used clinically, QALYs can be used
as a measure of disease burden, or combined with costs to esti-
mate cost-effectiveness.8 International guidelines for cost-effec-
tiveness recommend the use of QALYs for the assessment of
patient outcomes,9 and this has been followed by similar recom-
mendations at the national level in several countries, including
the UK. The core model addresses the direct effect of CAH on
patients including HRQoL and mortality associated with adrenal
crisis (AC). The submodels examine comorbidities associated
with CAH (Fig. 1).
The models are life tables tracking health-related events, LYs
and QALYs each year for men and women separately from age
18 years for life. National general population mortality rates are
applied and adjusted for increases in fatalities from AC and
CVD in the separate submodels.10 Baseline age-related utility for
the general population (measured with the EQ-5D scale) was
calculated using published evidence.11 Model parameters were
taken from the literature, where available.
Model subdomains
Direct CAH burden including Adrenal Crisis. Studies have
reported reduced QoL in adults with CAH, in particular reduced
general health and vitality.3,6,12 EQ-5D utility values were
derived from the SF-36 scores for CAH and the general
population reported in the CaHASE study.3,13
During illness, patients with CAH need to increase their dose
of glucocorticoid to meet the increased demand for adrenal ster-
oids, that is invoke ‘sick day rules’. If this is delayed, or not per-
formed, patients are more likely to have an AC requiring
attendance at hospital and parenteral steroids, and a proportion
of patients will die during an AC. There are limited data avail-
able regarding care for AC, so some parameters have had to be
estimated by a clinical expert (author RJR). Sensitivity analysis
was conducted on these parameters. All parameter values are
shown in Table 1.
The rate of AC was reported as 0066 per patient-year in
patients with primary adrenal insufficiency.14 Ninety-five per
cent confidence limits were estimated from the reported number
of AC and patient-years (0058, 0074). A similar rate of AC
(similarly defined) was reported in patients with CAH,15 but the
rate fell to 0038 per patient-year when the initial salt-wasting
crises which precipitated the diagnosis in infants were excluded.
This latter figure is used in sensitivity analysis.
Cardiovascular disease. Patients with CAH may have increased
Body Mass Index (BMI), blood pressure and cholesterol
compared to the general population, all known risk factors for
cardiovascular disease (CVD).3,17 A Swedish study reports CVD
mortality in Addison’s disease to be approximately twice that for
the general population, although no excess CVD mortality was
found in a similar Norwegian population.18,19 The model uses
data from the general population for CVD events and death and
applies to these a relative risk (RR) of CVD events for patients
with CAH, thus yielding estimates of CVD event rates for
patients with CAH. The RR of CVD in patients with CAH was
estimated using an approximation of the QRISK2 CVD risk
equation using mean differences in BMI and systolic blood
pressure between CAH and the general population from the
CAHASE study.3,17 This yielded a 10% increase in risk of CVD
events for women. Note for men in the CaHASE study, there
was no significant difference in BMI or blood pressure between
patients with CAH and the general population so the baseline
assumption is no increased CVD risk for men. For maximum
value sensitivity analysis, the results of Bergthorsdottir (2006)18
were used: RR of CVD of 231 for women and 197 for men.
For the minimum scenario, no increased risk of CVD arising
from CAH was assumed. The model includes incident angina,
stroke and MI events, deaths from stroke and MI, as well as allFig. 1 Diagram of the conceptual model.
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CVD deaths. CVD age-related event rates for the general
population were taken from national data20,21 (a Table S2 is
available summarizing this data). A conservative approach was
taken to estimate the HRQoL reductions due to CVD events:
the loss of HRQoL due to stroke or MI was applied in the year
of the event only leading to an underestimate of total QALY loss
associated with these events.22
Obesity. Women with CAH have an average BMI of 62 kg/m2
greater than the general population of similar age.3 Obesity has a
negative effect on HRQoL independent of the associated chronic
illnesses.23 High BMI particularly affects pain and mobility. Using
data from Macran (2004),23 a linear relationship was derived
showing a loss of 00033 in utility for every unit increase in BMI
(kg/m2) for BMI greater than 21 kg/m2 in a population of
median age 46 years. For men, there was no independent
relationship between BMI and utility, and no difference in BMI
between men with CAH and the general population.3,23
Bone fractures. Glucocorticoid treatment is known to reduce
BMD and put patients at increased risk of fractures, with
fracture risk associated with dose.24 The lifetime number of
fractures was estimated for people with CAH and the general
population (a Table S1 is available summarizing this data).
Baseline fracture incidence by age for nonvertebral and hip
fractures was taken from the literature.24,25 Similar data were
not identified for vertebral or forearm fractures: it was assumed
that the relationship between fracture incidence and age is the
same for forearm fractures as for all nonvertebral fractures and
that the relationship between age and fracture incidence for
vertebral fractures is similar to hip fractures, adjusted for
absolute incidence in both cases.24 It was assumed the mean
equivalent hydrocortisone dose for adults with CAH was
296 mg/day.3 Curves were fitted to data from van Staa26 to
establish the RR of fractures by glucocorticoid dose (daily
hydrocortisone dose equivalent mg/day = DD):
All fracture RR ¼ 000009  DD2 þ 0267  DDþ 1
Femur/hip fracture RR ¼ 00002  DD2 þ 00343  DDþ 1
Vertebral fracture RR ¼ 00702  DDþ 1
EQ-5D utility values were from Stevenson (2007).27 As no
utility for wrist fracture was reported, that for ‘other’ fractures
was used as this was the most conservative (highest). Excess
mortality from hip fractures was not considered, as mortality
directly attributable to fractures is relatively low, especially in
younger age groups (estimated 2% age 50–60 years, rising to
16% age 90 years or more).27
Fertility. CAH affects fertility in both men and women. In the
CaHASE study, 25% of women attempted to conceive, of which
54% were successful indicating that, of all women with classic
CAH, 135% conceived, and 115% sought fertility and failed.3 In
the same study, 37% of men attempted to conceive, of which 67%
were successful, so 25% of all men with classic CAH fathered
children and 12% sought fertility and failed.3 However, data on
fertility choices of both patients with CAH and the general
population are limited, and therefore, it is included as a sensitivity
analysis only. The NICE clinical guideline on fertility quotes
figures indicating that 92% of women in the general population
will conceive after 2 years and 93% after 3 years.28,29 However, a
study of infertility in UK general practice reports a rate of 59 per
1000 person-years, suggesting a far lower proportion of women
(approximately 06%) seeking help for infertility.30 The greater
estimate of 7% unwanted infertility is used in the model,28
adjusted for the proportion of couples seeking help for infertility
who already have at least one child (41%31): to be consistent with
the scenario for patients with CAH only totally infertile couples in
the general population are considered. Outcomes from a specialist
fertility clinic indicate a 51% success rate within 5 years, with
approximately half of all patients receiving active treatment.31 All
the data discussed refer to women: it has been assumed that men
in the general population are similarly affected by infertility.
There is little information on the effect of unwanted infertility
on HRQoL. The utility decrement (007) was taken from the
NICE fertility guideline and applied in the same way, that is a
constant decrement applied for life.28 Note this may overesti-
mate QALY losses from infertility if the utility decrement
decreases with time. In the absence of other data, it is assumed
that the utility decrement is the same for men. The utility decre-
ment is applied from the average age at which the general popu-
lation has their first child (Table 2).
Results
Core model – CAH
The model estimates that on average adults with CAH will
implement ‘sick day rules’ (doubling or tripling glucocorticoid
and/or use of parenteral therapy) 171 times over their lifetime
Table 1. Data used to estimate lifetime CAH burden
Mean Max Min Source
Sick day rules per year 3 6 1 Clinical expert (RJR)
Hospital for IV hydrocortisone per year 0066 0074 0038 Hahner 2010,14 Reisch 201215
Of which inpatient 075 1 025 Clinical expert (RJR)
P(death) after inpatient admission for AC 0025 0032 0005 Clinical expert (RJR), Rushworth 201416
Utility multiplier CAH 093 097 089 Derived from CaHASE (Arlt 2010,3 Rowen 200913)
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and attend hospital for AC on 11 occasions. In a population of
1000 over 200 will die of a condition complicated by AC result-
ing, on average, in a loss of 73 years of life, or 90 QALYs
(Fig. 2 and Table 3).
It can be seen that the direct effects of CAH and associated
AC are the main cause of excess morbidity and mortality in
adults with CAH. The comorbidities do not affect all patients
with CAH, and CVD and bone fractures affect people mostly
later in life. When comorbidities are considered the survival dif-
ference between adults with CAH and the general population is
74 years, or taking into account the effect on HRQoL, 102
QALYs. If the (uncertain) effects of infertility are included the
difference in QALYs increases to 106.
The effects of CVD are modest, but for the baseline model, an
increased risk of only 10% was estimated, and for women only.
Nevertheless, in a population of 1000 CAH women, they will
experience an estimated additional 11 MI, 41 strokes and 17
CVD deaths compared to the general population.
Obesity (independent of CVD effects) and bone fractures are
assumed to affect HRQoL and not survival and therefore have
no effect on LYs. Nevertheless, the estimated effect of obesity on
women’s QALYs is not negligible: with an average BMI of
62 kg/m2 greater than the general population of similar age,3
the estimated reduction in utility is 002 for women aged 46.
Over the adult lifetime, this leads to a loss of 13 QALYs for
CAH women compared to the general population.
The incidence of fractures is approximately doubled in per-
sons with CAH compared to the general population (Fig. 3).
For women, this means an average of one additional fracture
over their lifetime; for men 07 fractures. Despite this the esti-
mated effect of additional bone fractures on QALYs is relatively
small (Table 3), affecting people mainly in old age.
Sensitivity analysis
The sensitivity analysis focused on the core CAH/AC model as
almost all the difference in LYs and QALYs between adults with
CAH and the general population arise from the direct effects of
CAH. A sensitivity analysis on the RR of CVD for adults with
CAH is also presented given the uncertainty and potential effect
of this parameter on outcomes (Table 3).
The parameter that contributes to the greatest uncertainty in
the results is the average number of times a year adults with
CAH need to implement ‘sick day rules’. No data were available
for this parameter, which was estimated to be between one and
six times per year, with a baseline value of three. The estimated
number of deaths from conditions exacerbated by AC is related
to this parameter as the probability of death from AC is applied
to the number of patients admitted as inpatients for AC, which
in turn depends on the number needing to implement ‘sick day
Table 2. Fertility model parameters
Item Mean Source
CAH parameters
CAH seek fertility
Women 025 CaHASE Arlt 20103
Men 037
CAH succeed (of those seeking)
Women 054 CaHASE Arlt 20103
Men 067
General population parameters
Unwanted infertility
All 007 NICE 201328
Proportion no previous child
All 059 Pandey 201431
Successful outcome
All 051 Pandey 201431
All
Mean age 1st child
Women 279 ONS fertility 201332
Men 308 ONS fertility 2013
Utility decrement infertility
Women 007 NICE 201328
Men 007 Assumption
Fig. 2 Effect of CAH on survival.
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rules’. The other parameters in the CAH/AC module contribute
to a similar level of uncertainty: all, with the exception of CAH
utility, contributing to the estimated number of deaths from
AC.
A 10% increase in RR of CVD events for women only is esti-
mated for the baseline scenario: the maximum, based on obser-
vational evidence, uses a RR of approximately two.18 The
resulting additional CVD mortality reduces survival in adults
with CAH by approximately 2 years.
Discussion
Adults with CAH experience reduced HRQoL and reduced sur-
vival. In recent years, there has been a growing literature on the
Fig. 3 Lifetime average number of fractures per
person.
Table 3. Differences in LYs and QALYs between CAH and the general population, base case and sensitivity analysis
Item
Life years QALYs
Women Men All Women Men All
Base case
CAH/AC 754 677 725 922 875 904
Sensitivity
CAH utility – – – 735 692
Max 718
Min – – – 1110 1058 1090
AC sick day rules/year
Max 1394 1256 1342 1397 1320 1368
Min 266 238 255 562 538 553
Hospital for IV hydrocortisone/year
Max 838 753 806 984 933 965
Min 450 403 432 697 665 685
Of which inpatient
Max 979 880 942 1089 1031 1067
Min 266 238 255 562 538 553
P(death) following inpatient admission
Max 944 849 908 1063 1006 1041
Min 161 144 155 485 466 478
Base case
CVD 019 000 012 014 000 009
Sensitivity
RR of CVD
Max 217 213 216 162 167 164
Min 000 000 000 000 000 000
Base case
Obesity – – – 129 000 080
Bone fractures – – – 039 017 030
Total 773 677 737 1104 892 1024
© 2016 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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epidemiology of the condition but to our knowledge, no previ-
ous attempt has been made to estimate the overall lifetime bur-
den of CAH, including associated comorbidities. Our results
show that despite the many comorbidities experienced by adults
with CAH, it is CAH itself, and in particular the mortality aris-
ing from conditions exacerbated by AC, which results in average
survival being 7 years less than for the general population. Con-
sideration of the effect of reduced lifelong HRQoL gives an esti-
mated reduction of 9 QALYs. There is uncertainty in all the
model parameters associated with this estimate, and both the
number of times a year patients implement sick day rules and
the proportion of patients experiencing AC who are admitted as
inpatients were estimated by the authors. The effect of the
uncertainty in all the CAH/AC parameters on the results (LY
and QALYs) is of a similar order of magnitude, giving a range
in estimated reduction in survival of between 2 and 13 years,
and 5 to 14 QALYs.
CVD has a very limited effect on survival and QALYs in the
baseline model: the effect of CAH on CVD is uncertain as life-
saving glucocorticoid therapy was only introduced in the 1950s,
so there are few patients in their sixties. An increased risk of just
10% was applied for women only: CAH men in the CAHASE
study did not have increased BMI or systolic blood pressure
compared to the general population. The baseline analysis
assumes that the relationship between risk factors and CVD
events in the CAH population is the same as that for the general
population. In fact, there is some evidence that the CVD burden
in CAH may be much greater.18 Sensitivity analysis using an RR
of approximately two for CVD risk for both men and women,18
suggests CVD mortality may reduce survival in adults with CAH
by up to 2 years. Mortality is calculated separately in the CAH
core model and CVD submodel, so the mortality reductions are
not additive. The effect of CVD morbidity is underestimated as
the disutility of CVD events is only applied in the year of occur-
rence.
We did not include diabetes in our model as the relationship
between markers of insulin sensitivity and glucocorticoid treated
patients with CAH is complex. Patients with CAH and adrenal
insufficiency (AI) who are under replaced with glucocorticoid
are at risk of hypoglycaemia, and this is a presenting feature of
AI in neonates and children as cortisol reduces insulin sensitiv-
ity. The physiological rise in the early morning hours reduces
insulin sensitivity and protects from nocturnal hypoglycaemia,
and replacement of cortisol in patients with CAH has a similar
effect with a rise in HOMA-IR.33 Thus, the use of change in
HOMA-IR as a risk factor for diabetes is not appropriate in
CAH.
The effects of long-term glucocorticoid treatment on fractures
are well established, with risk increasing with higher doses.26
This relationship was used to model the likely increase in frac-
tures in adults with CAH. A recent paper has examined fractures
in patients with CAH and found no statistically significant rela-
tionship with GC exposure, although the sample size was
small.34 However, the authors did find an increase in fractures
associated with classic CAH compared to nonclassic CAH, which
suggests an increased fracture risk over that of the general popu-
lation. This may suggest an increased risk independent of GC
exposure; however, there is insufficient evidence at this time for
this to be reliably modelled.
Structural and hormonal problems inhibit fertility in adults
with CAH, and unwanted infertility has been shown to reduce
HRQoL, at least in women.35 Estimation of the consequences on
QALYs of unwanted infertility resulting from CAH is uncertain
as data are limited for the general population, especially men, as
well as for adults with CAH. Data reported in the CAHASE
study were used to estimate unwanted infertility in the CAH
population, but many subjects were of an age where their fertil-
ity choices may not have been final.3 Also, the data may under-
estimate latent desire for fertility as patients with CAH may be
discouraged from considering fertility.
This is the first attempt to model the overall disease burden
of CAH and naturally has the limitations of using historical
cross-sectional data from different populations. The model is
relatively simple, with a separate life table for each comorbidity
resulting in potential overestimation of the total effects when the
results of each are summed. However, given the dominance of
the direct effects of CAH/AC on outcomes, this has little effect
on the results. Caution needs to be taken in interpretation of
other published models when applied to CAH; however, we have
had to use these in the absence of validated models in CAH. For
example, our estimates of bone fractures come from the use of
glucocorticoids as anti-inflammatory agents, whereas in CAH it
is substitution therapy and there may be a balancing effect of
excess androgens. Similarly, obesity has a complex relationship
with fractures and bone density and this would be expected to
be more complex in the face of androgen and glucocorticoid
imbalance.
As a generic measure of health, QALYs are used to capture
the effects of treatments across many conditions. Their ability to
combine mortality and morbidity effects makes them useful for
complex conditions, such as those of the endocrine system. The
use of QALYs and cost-effectiveness analysis within diabetes has
shown how multiple clinical effects can be captured and evalu-
ated within this framework. However, the methods by which the
HRQoL of patients is captured have drawn criticism as they
have been found to be insensitive to clinical change in many sit-
uations. In our study, the HRQoL effects were measured using
the EQ-5D descriptive system and scoring algorithm,36 yet the
EQ-5D does not directly measure vitality which is an important
feature of CAH. As such, the HRQoL scores and QALYs may
underestimate the impact of CAH on health. Despite these
potential problems, an alternative summary measure of burden
of disease that is also applicable to cost-effectiveness analysis is
not available.
Development of the model has highlighted gaps in the evi-
dence, particularly intensity of care for AC, and the relationship
between control of CAH and risks of CVD, osteoporosis and
infertility. This modelling approach has the potential to assess
the long-term patient effects of therapeutic changes via their
impact on the estimated model parameters, for example num-
ber of sick day rules, BMI, systolic blood pressure and steroid
use.
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